Cargando…

Vitamin E and Alzheimer’s disease: what do we know so far?

Vitamin E has been proposed as a potential clinical intervention for Alzheimer’s disease (AD) given the plausibility of its various biological functions in influencing the neurodegenerative processes associated with the condition. The tocopherol and tocotrienol isoforms of vitamin E have multiple pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Browne, Declan, McGuinness, Bernadette, Woodside, Jayne V, McKay, Gareth J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6645610/
https://www.ncbi.nlm.nih.gov/pubmed/31409980
http://dx.doi.org/10.2147/CIA.S186760
_version_ 1783437499993948160
author Browne, Declan
McGuinness, Bernadette
Woodside, Jayne V
McKay, Gareth J
author_facet Browne, Declan
McGuinness, Bernadette
Woodside, Jayne V
McKay, Gareth J
author_sort Browne, Declan
collection PubMed
description Vitamin E has been proposed as a potential clinical intervention for Alzheimer’s disease (AD) given the plausibility of its various biological functions in influencing the neurodegenerative processes associated with the condition. The tocopherol and tocotrienol isoforms of vitamin E have multiple properties including potent antioxidant and anti-inflammatory characteristics, in addition to influences on immune function, cellular signalling and lowering cholesterol. Several of these roles offer a theoretical rationale for providing benefit for the treatment of AD-associated pathology. Diminished circulating concentrations of vitamin E have been demonstrated in individuals with AD. Reduced plasma levels have furthermore been associated with an increased risk of AD development while intake, particularly from dietary sources, may limit or reduce the rate of disease progression. This benefit may be linked to synergistic actions between vitamin E isoforms and other micronutrients. Nevertheless, randomised trials have found limited and inconsistent evidence of vitamin E supplementation as an effective clinical intervention. Thus, despite a strong rationale in support of a beneficial role for vitamin E for the treatment of AD, the evidence remains inconclusive. Several factors may partly explain this discrepancy and represent the difficulties of translating complex laboratory evidence and dietary interactions into clinical interventions. Methodological design limitations of existing randomised trials and restrictions to supplementation with a single vitamin E isoform may also limit the influence of effect. Moreover, several factors influence individual responsiveness to vitamin E intake and recent findings suggest variation in the underlying genetic architecture attenuates vitamin E biological availability and activity which likely contributes to the variation in clinical responsiveness and the failure of randomised trials to date. Importantly, the clinical safety of vitamin E remains controversial and warrants further investigation.
format Online
Article
Text
id pubmed-6645610
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-66456102019-08-13 Vitamin E and Alzheimer’s disease: what do we know so far? Browne, Declan McGuinness, Bernadette Woodside, Jayne V McKay, Gareth J Clin Interv Aging Review Vitamin E has been proposed as a potential clinical intervention for Alzheimer’s disease (AD) given the plausibility of its various biological functions in influencing the neurodegenerative processes associated with the condition. The tocopherol and tocotrienol isoforms of vitamin E have multiple properties including potent antioxidant and anti-inflammatory characteristics, in addition to influences on immune function, cellular signalling and lowering cholesterol. Several of these roles offer a theoretical rationale for providing benefit for the treatment of AD-associated pathology. Diminished circulating concentrations of vitamin E have been demonstrated in individuals with AD. Reduced plasma levels have furthermore been associated with an increased risk of AD development while intake, particularly from dietary sources, may limit or reduce the rate of disease progression. This benefit may be linked to synergistic actions between vitamin E isoforms and other micronutrients. Nevertheless, randomised trials have found limited and inconsistent evidence of vitamin E supplementation as an effective clinical intervention. Thus, despite a strong rationale in support of a beneficial role for vitamin E for the treatment of AD, the evidence remains inconclusive. Several factors may partly explain this discrepancy and represent the difficulties of translating complex laboratory evidence and dietary interactions into clinical interventions. Methodological design limitations of existing randomised trials and restrictions to supplementation with a single vitamin E isoform may also limit the influence of effect. Moreover, several factors influence individual responsiveness to vitamin E intake and recent findings suggest variation in the underlying genetic architecture attenuates vitamin E biological availability and activity which likely contributes to the variation in clinical responsiveness and the failure of randomised trials to date. Importantly, the clinical safety of vitamin E remains controversial and warrants further investigation. Dove 2019-07-18 /pmc/articles/PMC6645610/ /pubmed/31409980 http://dx.doi.org/10.2147/CIA.S186760 Text en © 2019 Browne et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Browne, Declan
McGuinness, Bernadette
Woodside, Jayne V
McKay, Gareth J
Vitamin E and Alzheimer’s disease: what do we know so far?
title Vitamin E and Alzheimer’s disease: what do we know so far?
title_full Vitamin E and Alzheimer’s disease: what do we know so far?
title_fullStr Vitamin E and Alzheimer’s disease: what do we know so far?
title_full_unstemmed Vitamin E and Alzheimer’s disease: what do we know so far?
title_short Vitamin E and Alzheimer’s disease: what do we know so far?
title_sort vitamin e and alzheimer’s disease: what do we know so far?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6645610/
https://www.ncbi.nlm.nih.gov/pubmed/31409980
http://dx.doi.org/10.2147/CIA.S186760
work_keys_str_mv AT brownedeclan vitamineandalzheimersdiseasewhatdoweknowsofar
AT mcguinnessbernadette vitamineandalzheimersdiseasewhatdoweknowsofar
AT woodsidejaynev vitamineandalzheimersdiseasewhatdoweknowsofar
AT mckaygarethj vitamineandalzheimersdiseasewhatdoweknowsofar